Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18283422 | 1.00 | OPRM1 (0.41) | OPRM1CYP1A2CYP2C9HPGDMAPK1 | |
| SCHEMBL5787559 | 1.00 | OPRM1 (0.41) | OPRM1CYP1A2CYP2C9HPGDMAPK1 | |
| SCHEMBL29881672 | 1.00 | OPRM1 (0.41) | OPRM1CYP1A2CYP2C9HPGDMAPK1 | |
| SCHEMBL23904632 | 0.90 | OPRM1 (0.41) | OPRM1TP53ALDH1A1TDP1GABRP | |
| SCHEMBL417108 | 0.85 | OPRM1 (0.50) | OPRM1TP53PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL3856709 | 0.85 | OPRM1 (0.50) | OPRM1TP53PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL3856955 | 0.85 | OPRM1 (0.50) | OPRM1TP53PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL29881540 | 0.85 | OPRM1 (0.50) | OPRM1TP53PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL21307765 | 0.83 | OPRM1 (0.50) | OPRM1TP53PLA2G1BPLA2G2ASIGMAR1 | |
| SCHEMBL18292460 | 0.83 | CYP1A2 (0.44) | OPRM1CYP1A2CYP2C9HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515935-B | Treatment or prevention of coronavirus infection | 中美华世通生物医药科技(武汉)股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-115515935-A | Treatment or prevention of coronavirus infection | 中美华世通生物医药科技(武汉)股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-111803501-B | Use of chiral chloroquine hydroxychloroquine for reducing cardiotoxicity | 南方科技大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-114057640-A | Asymmetric synthesis method of optically pure (R)/(S) -hydroxychloroquine side chain | 凯特立斯（深圳）科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-114057640-A | Asymmetric synthesis method of optically pure (R)/(S) -hydroxychloroquine side chain | 凯特立斯（深圳）科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20210052553-A1 | Use of Clemizole Compounds for Treatment of Inflammatory Conditions | EIGER GROUP INTERNATIONAL, INC. | 2021-02-25 | — | — | US | disclosed |
| CN-111803501-A | Application of chiral chloroquine hydroxychloroquine or salt thereof as anti-coronavirus drug target 3CL hydrolase inhibitor for reducing cardiotoxicity | 南方科技大学 | 2020-10-23 | — | — | CN | disclosed |
| CN-111793026-A | Hydroxychloroquine sulfate, crystal form of enantiomer thereof and preparation method of crystal form | 珠海润都制药股份有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-10688083-B2 | Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions | EIGER GROUP INTERNATIONAL, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10647677-B2 | Analogues of hydroxychloroquine (HCQ) without retinal toxicity | INOVIEM SCIENTIFIC (FR) | 2020-05-12 | — | — | US | disclosed |
| WO-2019165337-A1 | HIGH-YIELDING CONTINUOUS FLOW SYNTHESIS OF ANTIMALARIAL DRUG HYDROXYCHLOROQUINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-08-29 | — | — | WO | disclosed |
| US-20180200228-A1 | Use of Chloroquine and Clemizole Compounds for Treatment of Inflammatory and Cancerous Conditions | EIGER GROUP INTERNATIONAL, INC. | 2018-07-19 | — | — | US | disclosed |
| EP-3303295-A2 | ANALOGUES OF HYDROXYCHLOROQUINE (HCQ) WITHOUT RETINAL TOXICITY | Inoviem Scientific (FR) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193503-A2 | ANALOGUES OF HYDROXYCHLOROQUINE (HCQ) WITHOUT RETINAL TOXICITY | INOVIEM SCIENTIFIC (FR) | 2016-12-08 | — | — | WO | disclosed |
| CN-105693606-A | Asymmetric synthesis method of optically pure (R)/(S)-hydroxychloroquine | 西安科技大学 | 2016-06-22 | — | — | CN | disclosed |
| EP-0588430-B1 | Use of (S)-(+)-Hydroxychloroquine | SANOFI SA (FR) | 1998-05-27 | — | — | EP | disclosed |
| US-5314894-A | (S)-(+)-hydroxychloroquine | STERLING WINTHROP INC. (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0588430-A1 | (S)-(+)-Hydroxychloroquine | STERLING WINTHROP INC. (US) | 1994-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647677-B2 | Analogues of hydroxychloroquine (HCQ) without retinal toxicity | SSB, UACA, XPA | OPRM1 4515/4885CYP1A2 1963/4885CYP2C9 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.